{"transactions":[{"id":945913,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T16:00:11.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":0.34,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0001193125-26-004359","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000119312526004359/ownership.xml","form_type":"4"}},{"id":997599,"issuer":{"id":73047,"kind":"organization","name":"LAVA Therapeutics NV","symbol":"LVTX"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2025-11-17T16:30:15.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the \"Purchase Agreement\") in exchange for cash and contingent value rights (\"CVRs\") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option."}],"balance_after":0,"derivative":{"exercise_price":0.93,"expiration_date":"2035-02-12","underlying":"Common Shares","underlying_shares":33390},"source":{"system":"sec-edgar","filing":"0001328146-25-000004","document":"form4-11172025_041111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000132814625000004/form4-11172025_041111.xml","form_type":"4"}},{"id":1263383,"issuer":{"id":73047,"kind":"organization","name":"LAVA Therapeutics NV","symbol":"LVTX"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares (Right to Buy)","published_at":"2025-02-18T20:15:17.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":33390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date."}],"balance_after":33390,"derivative":{"exercise_price":0.93,"expiration_date":"2035-02-12","underlying":"Common Shares","underlying_shares":33390},"source":{"system":"sec-edgar","filing":"0001415889-25-004529","document":"form4-02182025_080214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000141588925004529/form4-02182025_080214.xml","form_type":"4"}},{"id":1313927,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T16:00:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":1.09,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-25-001105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000095017025001105/ownership.xml","form_type":"4"}},{"id":1687223,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T16:02:07.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":2.78,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-24-001830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000095017024001830/ownership.xml","form_type":"4"}},{"id":1844976,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T16:46:34.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.26,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001437749-23-018282","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000143774923018282/rdgdoc.xml","form_type":"4"}},{"id":1937735,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-27T16:05:02.000Z","date":"2023-03-23","kind":"exercise","planned":false,"acquired":false,"shares":9682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Stock Option became exercisable in five equal annual installments beginning March 23, 2017 and is fully vested. This stock option expired on March 23, 2023."}],"balance_after":96062,"derivative":{"exercise_price":2.86,"expiration_date":"2023-03-23","underlying":"Common Stock","underlying_shares":9682},"source":{"system":"sec-edgar","filing":"0001209191-23-021201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000120919123021201/doc4.xml","form_type":"4"}},{"id":1937734,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T16:05:02.000Z","date":"2023-03-23","kind":"sale","planned":false,"acquired":false,"shares":9325,"price":3.28,"value":30586.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale to cover exercise price of cashless exercise of stock option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":357,"source":{"system":"sec-edgar","filing":"0001209191-23-021201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000120919123021201/doc4.xml","form_type":"4"}},{"id":1937733,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T16:05:02.000Z","date":"2023-03-23","kind":"exercise","planned":false,"acquired":true,"shares":9682,"price":2.86,"value":27690.52,"ownership":{"direct":true},"balance_after":9682,"source":{"system":"sec-edgar","filing":"0001209191-23-021201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000120919123021201/doc4.xml","form_type":"4"}},{"id":2061956,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T16:10:31.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2023.  The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":2.66,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-001789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000120919123001789/doc4.xml","form_type":"4"}},{"id":2221865,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T19:03:25.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on the date of the Company's 2023 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.82,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001583648-22-000051","document":"wf-form4_165611178802913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000158364822000051/wf-form4_165611178802913.xml","form_type":"4"}},{"id":2443109,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T20:27:54.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2022.  The shares underlying the option are scheduled to vest in full on the anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":12.28,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-001052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000089924322001052/doc4.xml","form_type":"4"}},{"id":2506608,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-17T17:00:46.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":1361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in five equal annual installments beginning March 23, 2017."}],"balance_after":105744,"derivative":{"exercise_price":2.86,"expiration_date":"2023-03-23","underlying":"Common Stock","underlying_shares":1361},"source":{"system":"sec-edgar","filing":"0000899243-21-045070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000089924321045070/doc4.xml","form_type":"4"}},{"id":2506607,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-17T17:00:46.000Z","date":"2021-11-15","kind":"exercise","acquired":false,"shares":18815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in five equal annual installments beginning March 23, 2017."}],"balance_after":107105,"derivative":{"exercise_price":2.86,"expiration_date":"2023-03-23","underlying":"Common Stock","underlying_shares":18815},"source":{"system":"sec-edgar","filing":"0000899243-21-045070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000089924321045070/doc4.xml","form_type":"4"}},{"id":2506606,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T17:00:46.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":1361,"price":18.02,"value":24525.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.31, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-045070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000089924321045070/doc4.xml","form_type":"4"}},{"id":2506605,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T17:00:46.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":1361,"price":2.86,"value":3892.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020."}],"balance_after":1361,"source":{"system":"sec-edgar","filing":"0000899243-21-045070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000089924321045070/doc4.xml","form_type":"4"}},{"id":2506604,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T17:00:46.000Z","date":"2021-11-15","kind":"sale","acquired":false,"shares":18815,"price":17.92,"value":337164.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-045070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000089924321045070/doc4.xml","form_type":"4"}},{"id":2506603,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T17:00:46.000Z","date":"2021-11-15","kind":"exercise","acquired":true,"shares":18815,"price":2.86,"value":53810.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020."}],"balance_after":18815,"source":{"system":"sec-edgar","filing":"0000899243-21-045070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000089924321045070/doc4.xml","form_type":"4"}},{"id":2651400,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-29T17:26:07.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on the date of the Company's 2022 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":4,"expiration_date":"2031-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001562180-21-004560","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000156218021004560/primarydocument.xml","form_type":"4"}},{"id":2914894,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-06T16:44:09.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":12.36,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-21-000711","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000089924321000711/doc4.xml","form_type":"4"}},{"id":3099629,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-06-25T16:45:19.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on June 23, 2021, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.27,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001562180-20-004688","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000156218020004688/primarydocument.xml","form_type":"4"}},{"id":3299969,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-28T16:22:05.000Z","date":"2020-01-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":20000,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-20-000623","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000156218020000623/primarydocument.xml","form_type":"4"}},{"id":3317740,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-06T17:55:38.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy."}],"balance_after":8000,"derivative":{"exercise_price":16.31,"exercise_date":"2021-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-20-002060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000120919120002060/doc4.xml","form_type":"4"}},{"id":3683623,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-29T17:37:22.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.74,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-19-000572","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000156218019000572/primarydocument.xml","form_type":"4"}},{"id":3707872,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-03T18:38:19.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8000,"derivative":{"exercise_price":5.16,"exercise_date":"2020-01-02","expiration_date":"2026-01-02","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-19-001328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000120919119001328/doc4.xml","form_type":"4"}},{"id":3782830,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-10-25T17:19:59.000Z","date":"2018-10-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on October 24, 2019, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":30000,"derivative":{"exercise_price":4.46,"expiration_date":"2028-10-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-18-004280","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000156218018004280/primarydocument.xml","form_type":"4"}},{"id":3893548,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-14T17:30:20.000Z","date":"2018-06-12","kind":"exercise","acquired":true,"shares":9600,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9600,"derivative":{"exercise_price":14.24,"exercise_date":"2018-12-31","expiration_date":"2025-06-12","underlying":"Common Stock","underlying_shares":9600},"source":{"system":"sec-edgar","filing":"0001209191-18-037808","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000120919118037808/doc4.xml","form_type":"4"}},{"id":4062332,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:51:31.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":133000,"price":6.15,"value":817950.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":11.85,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":133000},"source":{"system":"sec-edgar","filing":"0001171843-18-001104","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184318001104/formfour.xml","form_type":"4"}},{"id":4062331,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:51:31.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":87203,"price":4.2,"value":366252.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":13.8,"expiration_date":"2026-03-02","underlying":"Common Stock","underlying_shares":87203},"source":{"system":"sec-edgar","filing":"0001171843-18-001104","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184318001104/formfour.xml","form_type":"4"}},{"id":4062330,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:51:31.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":38500,"price":3.18,"value":122430.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":14.82,"expiration_date":"2025-03-04","underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0001171843-18-001104","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184318001104/formfour.xml","form_type":"4"}},{"id":4062329,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:51:31.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":250000,"price":9.67,"value":2417500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":8.33,"expiration_date":"2024-10-27","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001171843-18-001104","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184318001104/formfour.xml","form_type":"4"}},{"id":4062328,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Common Stock, Class A","published_at":"2018-02-13T16:51:31.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":44856,"price":18,"value":807408.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the \"Merger Agreement\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001171843-18-001104","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184318001104/formfour.xml","form_type":"4"}},{"id":4106943,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2018-01-04T17:16:08.000Z","date":"2017-12-31","kind":"grant","acquired":true,"shares":329,"price":9.1,"value":2993.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock."}],"balance_after":44856,"source":{"system":"sec-edgar","filing":"0001171843-18-000178","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184318000178/formfour.xml","form_type":"4"}},{"id":4116888,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Common Stock, Class A","published_at":"2018-01-02T17:00:26.000Z","date":"2017-12-28","kind":"tax_withholding","acquired":false,"shares":27496,"price":17.98,"value":494378.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported represents the non-discretionary withholding of shares to satisfy the reporting person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units."},{"field":"shares","element":"transactionShares","label":"F2","text":"Common stock originally granted consists of restricted stocked units; this award was originally scheduled to vest on March 2, 2020, but was accelerated to vest on December 28, 2017."}],"balance_after":44527,"source":{"system":"sec-edgar","filing":"0001171843-18-000049","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184318000049/formfour.xml","form_type":"4"}},{"id":4136140,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-12-11T17:30:22.000Z","date":"2017-12-07","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant has a graded vesting schedule.  Date Exercisable will vary for each vesting tranche."}],"balance_after":242567,"derivative":{"exercise_price":8.33,"expiration_date":"2024-10-27","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001171843-17-007595","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317007595/formfour.xml","form_type":"4"}},{"id":4136139,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Common Stock, Class A","published_at":"2017-12-11T17:30:22.000Z","date":"2017-12-07","kind":"sale","acquired":false,"shares":50000,"price":16.5,"value":825000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Multiple lots for the same price for this order have been combined."}],"balance_after":2023,"source":{"system":"sec-edgar","filing":"0001171843-17-007595","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317007595/formfour.xml","form_type":"4"}},{"id":4136138,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Common Stock, Class A","published_at":"2017-12-11T17:30:22.000Z","date":"2017-12-07","kind":"exercise","acquired":true,"shares":50000,"price":8.33,"value":416500.0,"ownership":{"direct":true},"balance_after":52023,"source":{"system":"sec-edgar","filing":"0001171843-17-007595","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317007595/formfour.xml","form_type":"4"}},{"id":4190828,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-10-05T16:40:15.000Z","date":"2017-09-30","kind":"grant","acquired":true,"shares":330,"price":9.1,"value":3003.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2017 through September 30, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 3, 2017 closing price of the issuer's common stock."}],"balance_after":2023,"source":{"system":"sec-edgar","filing":"0001171843-17-005959","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317005959/formfour.xml","form_type":"4"}},{"id":4260745,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-07-07T16:46:13.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":336,"price":8.93,"value":3000.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period April 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the June 30, 2017 closing price of the issuer's common stock."}],"balance_after":1693,"source":{"system":"sec-edgar","filing":"0001171843-17-004004","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317004004/formfour.xml","form_type":"4"}},{"id":4326413,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-05-10T16:03:53.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":321,"price":9.35,"value":3001.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period January 1, 2017 through March 31, 2017. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the March 31, 2017 closing price of the issuer's common stock."}],"balance_after":1357,"source":{"system":"sec-edgar","filing":"0001171843-17-002920","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317002920/formfour.xml","form_type":"4"}},{"id":4394506,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-03-08T17:02:51.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":133000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest over a four-year period, with 25% vesting on March 2, 2018, and the remaining 75% vesting in equal monthly increments over the three-year period thereafter."}],"balance_after":626270,"derivative":{"exercise_price":11.85,"expiration_date":"2027-03-02","underlying":"Class A Common Stock","underlying_shares":133000},"source":{"system":"sec-edgar","filing":"0001171843-17-001363","document":"f4_kiener030817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317001363/f4_kiener030817.xml","form_type":"4"}},{"id":4394505,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common stock","published_at":"2017-03-08T17:02:51.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock granted consists of restricted stock units that vest on March 2, 2020."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001171843-17-001363","document":"f4_kiener030817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317001363/f4_kiener030817.xml","form_type":"4"}},{"id":4496069,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2017-01-06T16:03:17.000Z","date":"2016-12-31","kind":"grant","acquired":true,"shares":287,"price":10.46,"value":3002.02,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period October 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the September 30, 2016 closing price of the issuer's common stock."}],"balance_after":1036,"source":{"system":"sec-edgar","filing":"0001171843-17-000125","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184317000125/formfour.xml","form_type":"4"}},{"id":4576041,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock, Class A (ESPP)","published_at":"2016-10-21T16:06:26.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":320,"price":9.38,"value":3001.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of common stock pursuant to the issuer's Employee Stock Purchase Plan (ESPP) for the period July 1, 2016 through September 30, 2016.  This transaction is exempt under Rule 16(b)-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at 85% of the July 1, 2016 closing price of the issuer's common stock."}],"balance_after":749,"source":{"system":"sec-edgar","filing":"0001171843-16-012576","document":"f4_kiener102116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000117184316012576/f4_kiener102116.xml","form_type":"4"}}]}